PanCareSurPass Project HL7 FHIR Implementation Guide
1.0.0 - release 150

PanCareSurPass Project HL7 FHIR Implementation Guide, published by PanCareSurPass Project. This guide is not an authorized publication; it is the continuous build for version 1.0.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/hl7-eu/pcsp/ and changes regularly. See the Directory of published versions

## ValueSet: Antineoplastic and immunostimulating agents

Official URL: http://hl7.eu/fhir/ig/pcsp/ValueSet/drugsAtc-eu-pcsp | Version: 1.0.0
Active as of 2026-01-16 | Computable Name: VsPcspAtcCodes

List of WHO ATC codes for antineoplastic and immunostimulating agents.

References

- MedicationAdministration: Chemotherapy

### Logical Definition (CLD)

- Include these codes as defined in `http://www.whocc.no/atc` version Not Stated (use latest from terminology server)

  Code | Display
  L01AA01 | Cyclophosphamide
  L01AA02 | Chlorambucil
  L01AA03 | Melphalan
  L01AA05 | Chlormethine
  L01AA06 | Ifosfamide
  L01AA07 | Trofosfamide
  L01AA08 | Prednimustine
  L01AA09 | Bendamustine
  L01AB01 | Busulfan
  L01AB02 | Treosulfan
  L01AB03 | Mannosulfan
  L01AC01 | Thiotepa
  L01AC02 | Triaziquone
  L01AC03 | Carboquone
  L01AD01 | Carmustine
  L01AD02 | Lomustine
  L01AD03 | Semustine
  L01AD04 | Streptozocin
  L01AD05 | Fotemustine
  L01AD06 | Nimustine
  L01AD07 | Ranimustine
  L01AG01 | Etoglucid
  L01AX | Peptichemio
  L01AX01 | Mitobronitol
  L01AX02 | Pipobroman
  L01AX03 | Temozolomide
  L01AX04 | Dacarbazine
  L01BA01 | Methotrexate
  L01BA03 | Raltitrexed
  L01BA04 | Pemetrexed
  L01BA05 | Pralatrexate
  L01BB02 | Mercaptopurine
  L01BB03 | Thioguanine
  L01BB04 | Cladribine
  L01BB05 | Fludarabine
  L01BB06 | Clofarabine
  L01BB07 | Nelarabine
  L01BC01 | Cytarabine
  L01BC02 | Fluorouracil
  L01BC03 | Tegafur
  L01BC04 | Carmofur
  L01BC05 | Gemcitabine
  L01BC06 | Capecitabine
  L01BC07 | Azacitidine
  L01BC08 | Decitabine
  L01BC52 | Fluorouracil, combinations
  L01BC53 | Tegafur, combinations
  L01BC59 | Trifluridine, combinations
  L01CA01 | Vinblastine
  L01CA02 | Vincristine
  L01CA03 | Vindesine
  L01CA04 | Vinorelbine
  L01CA05 | Vinflunine
  L01CA06 | Vintafolide
  L01CB01 | Etoposide
  L01CB02 | Teniposide
  L01CC01 | Demecolcine
  L01CD01 | Paclitaxel
  L01CD02 | Docetaxel
  L01CD03 | Paclitaxel poliglumex
  L01CD04 | Cabazitaxel
  L01CX01 | Trabectedin
  L01DA01 | Dactinomycin
  L01DB01 | Doxorubicin
  L01DB02 | Daunorubicin
  L01DB03 | Epirubicin
  L01DB04 | Aclarubicin
  L01DB05 | Zorubicin
  L01DB06 | Idarubicin
  L01DB07 | Mitoxantrone
  L01DB08 | Pirarubicin
  L01DB09 | Valrubicin
  L01DB10 | Amrubicin
  L01DB11 | Pixantrone
  L01DC01 | Bleomycin
  L01DC02 | Mithramycin
  L01DC03 | Mitomycin
  L01DC04 | Ixabepilone
  L01XA01 | Cisplatin
  L01XA02 | Carboplatin
  L01XA03 | Oxaliplatin
  L01XA04 | Satraplatin
  L01XA05 | Polyplatillen
  L01XB01 | Procarbazine
  L01FX01 | Edrecolomab
  L01FA01 | Rituximab
  L01FD01 | Trastuzumab
  L04AG06 | Alemtuzumab
  L01FX02 | Gemtuzumab
  L01FE01 | Cetuximab
  L01FG01 | Bevacizumab
  L01FE02 | Panitumumab
  L01FX03 | Catumaxomab
  L01FA02 | Ofatumumab
  L01FX04 | Ipilimumab
  L01FX05 | Brentuximab vedotin
  L01FD02 | Pertuzumab
  L01FD03 | Trastuzumab emtansine
  L01FA03 | Obinutuzumab
  L01FX06 | Dinutuximab
  L01FF01 | Nivolumab
  L01FF02 | Pembrolizumab
  L01FX07 | Blinatumomab
  L01FG02 | Ramucirumab
  L01FE03 | Necitumumab
  L01FX08 | Elotuzumab
  L01FC01 | Daratumumab
  L01FX09 | Mogamulizumab
  L01FB01 | Inotuzumab ozogamicin
  L01FX10 | Olaratumab
  L01XD01 | Porfimer sodium
  L01XD03 | Methyl aminolevulinate
  L01XD04 | Aminolevulinic acid
  L01XD05 | Temoporfin
  L01XD06 | Efaproxiral
  L01EA01 | Imatinib
  L01EB01 | Gefitinib
  L01EB02 | Erlotinib
  L01EX01 | Sunitinib
  L01EX02 | Sorafenib
  L01EA02 | Dasatinib
  L01EH01 | Lapatinib
  L01EA03 | Nilotinib
  L01EG01 | Temsirolimus
  L01EG02 | Everolimus
  L01EX03 | Pazopanib
  L01EX04 | Vandetanib
  L01EB03 | Afatinib
  L01EA04 | Bosutinib
  L01EC01 | Vemurafenib
  L01ED01 | Crizotinib
  L01EK01 | Axitinib
  D11AH09 | Ruxolitinib
  L01EG03 | Ridaforolimus
  L01EX05 | Regorafenib
  L01EX06 | Masitinib
  L01EC02 | Dabrafenib
  L01EA05 | Ponatinib
  L01EE01 | Trametinib
  L01EX07 | Cabozantinib
  L01EL01 | Ibrutinib
  L01ED02 | Ceritinib
  L01EX08 | Lenvatinib
  L01EX09 | Nintedanib
  L01EK02 | Cediranib
  L01EF01 | Palbociclib
  L01EK03 | Tivozanib
  L01EB04 | Osimertinib
  L01ED03 | Alectinib
  L01EB05 | Rociletinib
  L01EE02 | Cobimetinib
  L01EX10 | Midostaurin
  L01EB06 | Olmutinib
  L01XX | Other antineoplastic agent
  L01XX01 | Amsacrine
  L01XX02 | Asparaginase
  L01XX03 | Altretamine
  L01XX05 | Hydroxycarbamide
  L01XX07 | Lonidamine
  L01XX08 | Pentostatin
  P01CX04 | Miltefosine
  L01XX10 | Masoprocol
  L01XX11 | Estramustine
  D10AD01 | Tretinoin
  L01XX16 | Mitoguazone
  L01CE01 | Topotecan
  L01XX18 | Tiazofurine
  L01CE02 | Irinotecan
  D11AH04 | Alitretinoin
  L01XX23 | Mitotane
  L01XX24 | Pegaspargase
  L01XF03 | Bexarotene
  L01XX27 | Arsenic trioxide
  L01XX29 | Denileukin diftitox
  L01XG01 | Bortezomib
  L01XX33 | Celecoxib
  L01XX35 | Anagrelide
  L01XX36 | Oblimersen
  L01XL01 | Sitimagene ceradenovec
  L01XH01 | Vorinostat
  L01XH02 | Romidepsin
  L01XX40 | Omacetaxine mepesuccinate
  L01XX41 | Eribulin
  L01XH03 | Panobinostat
  L01XJ01 | Vismodegib
  L01XX44 | Aflibercept
  L01XG02 | Carfilzomib
  L01XK01 | Olaparib
  L01EM01 | Idelalisib
  L01XJ02 | Sonidegib
  L01XH04 | Belinostat
  L01XG03 | Ixazomib
  L01XL02 | Talimogene laherparepvec
  L01XX52 | Venetoclax
  L01XX53 | Vosaroxin
  L01XY | Combination of antineoplastic agents
  G03CB02 | Diethylstilbestrol
  L02AA02 | Polyestradiol phosphate
  G03CA01 | Ethinylestradiol
  L02AA04 | Fosfestrol
  G03AC05 | Megestrol
  G03AC06 | Medroxyprogesterone
  G03DA01 | Gestonorone
  L02AE01 | Buserelin
  L02AE02 | Leuprorelin
  L02AE03 | Goserelin
  L02AE04 | Triptorelin
  L02AE05 | Histrelin
  L02BA01 | Tamoxifen
  L02BA02 | Toremifene
  L02BA03 | Fulvestrant
  L02BB01 | Flutamide
  L02BB02 | Nilutamide
  L02BB03 | Bicalutamide
  L02BB04 | Enzalutamide
  L02BG01 | Aminogluthetimide
  L02BG02 | Formestane
  L02BG03 | Anastrozole
  L02BG04 | Letrozole
  L02BG05 | Vorozole
  L02BG06 | Exemestane
  L02BX01 | Abarelix
  L02BX02 | Degarelix
  L02BX03 | Abiraterone
  L03AA02 | Filgrastim
  L03AA03 | Molgramostim
  L03AA09 | Sargramostim
  L03AA10 | Lenograstim
  L03AA12 | Ancestim
  L03AA13 | Pegfilgrastim
  L03AA14 | Lipegfilgrastim
  L03AA15 | Balugrastim
  L03AA16 | Empegfilgrastim
  L03AB01 | Interferon alfa natural
  L03AB02 | Interferon beta natural
  L03AB03 | Interferon gamma
  L03AB04 | Interferon alfa-2a
  L03AB05 | Interferon alfa-2b
  L03AB06 | Interferon alfa-n1
  L03AB07 | Interferon beta-1a
  L03AB08 | Interferon beta-1b
  L03AB09 | Interferon alfacon-1
  L03AB10 | Peginterferon alfa-2b
  L03AB11 | Peginterferon alfa-2a
  L03AB12 | Albinterferon alfa-2b
  L03AB13 | Peginterferon beta-1a
  L03AB14 | Cepeginterferon alfa-2b
  L03AB60 | Peginterferon alfa-2b, combinations
  L03AB61 | Peginterferon alfa-2a, combinations
  L03AC01 | Aldesleukin
  L03AC02 | Oprelvekin
  L03AX01 | Lentinan
  L03AX02 | Roquinimex
  L03AX03 | BCG vaccine
  L03AX04 | Pegademase
  L03AX05 | Pidotimod
  L03AX07 | Poly I:C
  L03AX08 | Poly ICLC
  L03AX09 | Thymopentin
  L03AX10 | Immunocyanin
  L03AX11 | Tasonermin
  L03AX12 | Melanoma vaccine
  L03AX13 | Glatiramer acetate
  L03AX14 | Histamine dihydrochloride
  L03AX15 | Mifamurtide
  L03AX16 | Plerixafor
  L03AX17 | Sipuleucel-T
  L03AX18 | Cridanimod
  L03AX19 | Dasiprotimut-T
  L04AG01 | Muromonab-CD3
  L04AA03 | Antilymphocyte immunoglobulin (horse)
  L04AA04 | Antithymocyte immunoglobulin (rabbit)
  L04AA06 | Mycophenolic acid
  L01EG04 | Sirolimus
  L04AK01 | Leflunomide
  L04AA15 | Alefacept
  L04AA19 | Gusperimus
  L04AG02 | Efalizumab
  L04AA22 | Abetimus
  L04AG03 | Natalizumab
  L04AA24 | Abatacept
  L04AJ01 | Eculizumab
  L04AG04 | Belimumab
  L04AE01 | Fingolimod
  L04AA28 | Belatacept
  L04AF01 | Tofacitinib
  L04AK02 | Teriflunomide
  L04AA32 | Apremilast
  L04AG05 | Vedolizumab
  L04AG07 | Begelomab
  L04AG08 | Ocrelizumab
  L04AF02 | Baricitinib
  L04AB01 | Etanercept
  L04AB02 | Infliximab
  L04AB03 | Afelimomab
  L04AB04 | Adalimumab
  L04AB05 | Certolizumab pegol
  L04AB06 | Golimumab
  L04AC01 | Daclizumab
  L04AC02 | Basiliximab
  L04AC03 | Anakinra
  L04AC04 | Rilonacept
  L04AC05 | Ustekinumab
  R03DX09 | Mepolizumab
  L04AC07 | Tocilizumab
  L04AC08 | Canakinumab
  L04AC09 | Briakinumab
  L04AC10 | Secukinumab
  L04AC11 | Siltuximab
  L04AC12 | Brodalumab
  L04AC13 | Ixekizumab
  L04AC14 | Sarilumab
  L04AD01 | Ciclosporin
  D11AH01 | Tacrolimus
  L04AD03 | Voclosporin
  L04AX01 | Azathioprine
  L04AX02 | Thalidomide
  L04AX04 | Lenalidomide
  L04AX05 | Pirfenidone
  L04AX06 | Pomalidomide

### Expansion

Expansion from tx.fhir.org based on codesystem WHO ATC version 2025

This value set contains 320 concepts

System | Code | Display (en) | JSON | XML
`http://www.whocc.no/atc` | L01AA01 | cyclophosphamide |  |
`http://www.whocc.no/atc` | L01AA02 | chlorambucil |  |
`http://www.whocc.no/atc` | L01AA03 | melphalan |  |
`http://www.whocc.no/atc` | L01AA05 | chlormethine |  |
`http://www.whocc.no/atc` | L01AA06 | ifosfamide |  |
`http://www.whocc.no/atc` | L01AA07 | trofosfamide |  |
`http://www.whocc.no/atc` | L01AA08 | prednimustine |  |
`http://www.whocc.no/atc` | L01AA09 | bendamustine |  |
`http://www.whocc.no/atc` | L01AB01 | busulfan |  |
`http://www.whocc.no/atc` | L01AB02 | treosulfan |  |
`http://www.whocc.no/atc` | L01AB03 | mannosulfan |  |
`http://www.whocc.no/atc` | L01AC01 | thiotepa |  |
`http://www.whocc.no/atc` | L01AC02 | triaziquone |  |
`http://www.whocc.no/atc` | L01AC03 | carboquone |  |
`http://www.whocc.no/atc` | L01AD01 | carmustine |  |
`http://www.whocc.no/atc` | L01AD02 | lomustine |  |
`http://www.whocc.no/atc` | L01AD03 | semustine |  |
`http://www.whocc.no/atc` | L01AD04 | streptozocin |  |
`http://www.whocc.no/atc` | L01AD05 | fotemustine |  |
`http://www.whocc.no/atc` | L01AD06 | nimustine |  |
`http://www.whocc.no/atc` | L01AD07 | ranimustine |  |
`http://www.whocc.no/atc` | L01AG01 | etoglucid |  |
`http://www.whocc.no/atc` | L01AX | Other alkylating agents |  |
`http://www.whocc.no/atc` | L01AX01 | mitobronitol |  |
`http://www.whocc.no/atc` | L01AX02 | pipobroman |  |
`http://www.whocc.no/atc` | L01AX03 | temozolomide |  |
`http://www.whocc.no/atc` | L01AX04 | dacarbazine |  |
`http://www.whocc.no/atc` | L01BA01 | methotrexate |  |
`http://www.whocc.no/atc` | L01BA03 | raltitrexed |  |
`http://www.whocc.no/atc` | L01BA04 | pemetrexed |  |
`http://www.whocc.no/atc` | L01BA05 | pralatrexate |  |
`http://www.whocc.no/atc` | L01BB02 | mercaptopurine |  |
`http://www.whocc.no/atc` | L01BB03 | tioguanine |  |
`http://www.whocc.no/atc` | L01BB04 | cladribine |  |
`http://www.whocc.no/atc` | L01BB05 | fludarabine |  |
`http://www.whocc.no/atc` | L01BB06 | clofarabine |  |
`http://www.whocc.no/atc` | L01BB07 | nelarabine |  |
`http://www.whocc.no/atc` | L01BC01 | cytarabine |  |
`http://www.whocc.no/atc` | L01BC02 | fluorouracil |  |
`http://www.whocc.no/atc` | L01BC03 | tegafur |  |
`http://www.whocc.no/atc` | L01BC04 | carmofur |  |
`http://www.whocc.no/atc` | L01BC05 | gemcitabine |  |
`http://www.whocc.no/atc` | L01BC06 | capecitabine |  |
`http://www.whocc.no/atc` | L01BC07 | azacitidine |  |
`http://www.whocc.no/atc` | L01BC08 | decitabine |  |
`http://www.whocc.no/atc` | L01BC52 | fluorouracil, combinations |  |
`http://www.whocc.no/atc` | L01BC53 | tegafur, combinations |  |
`http://www.whocc.no/atc` | L01BC59 | trifluridine, combinations |  |
`http://www.whocc.no/atc` | L01CA01 | vinblastine |  |
`http://www.whocc.no/atc` | L01CA02 | vincristine |  |
`http://www.whocc.no/atc` | L01CA03 | vindesine |  |
`http://www.whocc.no/atc` | L01CA04 | vinorelbine |  |
`http://www.whocc.no/atc` | L01CA05 | vinflunine |  |
`http://www.whocc.no/atc` | L01CA06 | vintafolide |  |
`http://www.whocc.no/atc` | L01CB01 | etoposide |  |
`http://www.whocc.no/atc` | L01CB02 | teniposide |  |
`http://www.whocc.no/atc` | L01CC01 | demecolcine |  |
`http://www.whocc.no/atc` | L01CD01 | paclitaxel |  |
`http://www.whocc.no/atc` | L01CD02 | docetaxel |  |
`http://www.whocc.no/atc` | L01CD03 | paclitaxel poliglumex |  |
`http://www.whocc.no/atc` | L01CD04 | cabazitaxel |  |
`http://www.whocc.no/atc` | L01CX01 | trabectedin |  |
`http://www.whocc.no/atc` | L01DA01 | dactinomycin |  |
`http://www.whocc.no/atc` | L01DB01 | doxorubicin |  |
`http://www.whocc.no/atc` | L01DB02 | daunorubicin |  |
`http://www.whocc.no/atc` | L01DB03 | epirubicin |  |
`http://www.whocc.no/atc` | L01DB04 | aclarubicin |  |
`http://www.whocc.no/atc` | L01DB05 | zorubicin |  |
`http://www.whocc.no/atc` | L01DB06 | idarubicin |  |
`http://www.whocc.no/atc` | L01DB07 | mitoxantrone |  |
`http://www.whocc.no/atc` | L01DB08 | pirarubicin |  |
`http://www.whocc.no/atc` | L01DB09 | valrubicin |  |
`http://www.whocc.no/atc` | L01DB10 | amrubicin |  |
`http://www.whocc.no/atc` | L01DB11 | pixantrone |  |
`http://www.whocc.no/atc` | L01DC01 | bleomycin |  |
`http://www.whocc.no/atc` | L01DC02 | plicamycin |  |
`http://www.whocc.no/atc` | L01DC03 | mitomycin |  |
`http://www.whocc.no/atc` | L01DC04 | ixabepilone |  |
`http://www.whocc.no/atc` | L01XA01 | cisplatin |  |
`http://www.whocc.no/atc` | L01XA02 | carboplatin |  |
`http://www.whocc.no/atc` | L01XA03 | oxaliplatin |  |
`http://www.whocc.no/atc` | L01XA04 | satraplatin |  |
`http://www.whocc.no/atc` | L01XA05 | polyplatillen |  |
`http://www.whocc.no/atc` | L01XB01 | procarbazine |  |
`http://www.whocc.no/atc` | L01FX01 | edrecolomab |  |
`http://www.whocc.no/atc` | L01FA01 | rituximab |  |
`http://www.whocc.no/atc` | L01FD01 | trastuzumab |  |
`http://www.whocc.no/atc` | L04AG06 | alemtuzumab |  |
`http://www.whocc.no/atc` | L01FX02 | gemtuzumab ozogamicin |  |
`http://www.whocc.no/atc` | L01FE01 | cetuximab |  |
`http://www.whocc.no/atc` | L01FG01 | bevacizumab |  |
`http://www.whocc.no/atc` | L01FE02 | panitumumab |  |
`http://www.whocc.no/atc` | L01FX03 | catumaxomab |  |
`http://www.whocc.no/atc` | L01FA02 | ofatumumab |  |
`http://www.whocc.no/atc` | L01FX04 | ipilimumab |  |
`http://www.whocc.no/atc` | L01FX05 | brentuximab vedotin |  |
`http://www.whocc.no/atc` | L01FD02 | pertuzumab |  |
`http://www.whocc.no/atc` | L01FD03 | trastuzumab emtansine |  |
`http://www.whocc.no/atc` | L01FA03 | obinutuzumab |  |
`http://www.whocc.no/atc` | L01FX06 | dinutuximab beta |  |
`http://www.whocc.no/atc` | L01FF01 | nivolumab |  |
`http://www.whocc.no/atc` | L01FF02 | pembrolizumab |  |
`http://www.whocc.no/atc` | L01FX07 | blinatumomab |  |
`http://www.whocc.no/atc` | L01FG02 | ramucirumab |  |
`http://www.whocc.no/atc` | L01FE03 | necitumumab |  |
`http://www.whocc.no/atc` | L01FX08 | elotuzumab |  |
`http://www.whocc.no/atc` | L01FC01 | daratumumab |  |
`http://www.whocc.no/atc` | L01FX09 | mogamulizumab |  |
`http://www.whocc.no/atc` | L01FB01 | inotuzumab ozogamicin |  |
`http://www.whocc.no/atc` | L01FX10 | olaratumab |  |
`http://www.whocc.no/atc` | L01XD01 | porfimer sodium |  |
`http://www.whocc.no/atc` | L01XD03 | methyl aminolevulinate |  |
`http://www.whocc.no/atc` | L01XD04 | aminolevulinic acid |  |
`http://www.whocc.no/atc` | L01XD05 | temoporfin |  |
`http://www.whocc.no/atc` | L01XD06 | efaproxiral |  |
`http://www.whocc.no/atc` | L01EA01 | imatinib |  |
`http://www.whocc.no/atc` | L01EB01 | gefitinib |  |
`http://www.whocc.no/atc` | L01EB02 | erlotinib |  |
`http://www.whocc.no/atc` | L01EX01 | sunitinib |  |
`http://www.whocc.no/atc` | L01EX02 | sorafenib |  |
`http://www.whocc.no/atc` | L01EA02 | dasatinib |  |
`http://www.whocc.no/atc` | L01EH01 | lapatinib |  |
`http://www.whocc.no/atc` | L01EA03 | nilotinib |  |
`http://www.whocc.no/atc` | L01EG01 | temsirolimus |  |
`http://www.whocc.no/atc` | L01EG02 | everolimus |  |
`http://www.whocc.no/atc` | L01EX03 | pazopanib |  |
`http://www.whocc.no/atc` | L01EX04 | vandetanib |  |
`http://www.whocc.no/atc` | L01EB03 | afatinib |  |
`http://www.whocc.no/atc` | L01EA04 | bosutinib |  |
`http://www.whocc.no/atc` | L01EC01 | vemurafenib |  |
`http://www.whocc.no/atc` | L01ED01 | crizotinib |  |
`http://www.whocc.no/atc` | L01EK01 | axitinib |  |
`http://www.whocc.no/atc` | D11AH09 | ruxolitinib |  |
`http://www.whocc.no/atc` | L01EG03 | ridaforolimus |  |
`http://www.whocc.no/atc` | L01EX05 | regorafenib |  |
`http://www.whocc.no/atc` | L01EX06 | masitinib |  |
`http://www.whocc.no/atc` | L01EC02 | dabrafenib |  |
`http://www.whocc.no/atc` | L01EA05 | ponatinib |  |
`http://www.whocc.no/atc` | L01EE01 | trametinib |  |
`http://www.whocc.no/atc` | L01EX07 | cabozantinib |  |
`http://www.whocc.no/atc` | L01EL01 | ibrutinib |  |
`http://www.whocc.no/atc` | L01ED02 | ceritinib |  |
`http://www.whocc.no/atc` | L01EX08 | lenvatinib |  |
`http://www.whocc.no/atc` | L01EX09 | nintedanib |  |
`http://www.whocc.no/atc` | L01EK02 | cediranib |  |
`http://www.whocc.no/atc` | L01EF01 | palbociclib |  |
`http://www.whocc.no/atc` | L01EK03 | tivozanib |  |
`http://www.whocc.no/atc` | L01EB04 | osimertinib |  |
`http://www.whocc.no/atc` | L01ED03 | alectinib |  |
`http://www.whocc.no/atc` | L01EB05 | rociletinib |  |
`http://www.whocc.no/atc` | L01EE02 | cobimetinib |  |
`http://www.whocc.no/atc` | L01EX10 | midostaurin |  |
`http://www.whocc.no/atc` | L01EB06 | olmutinib |  |
`http://www.whocc.no/atc` | L01XX | Other antineoplastic agents |  |
`http://www.whocc.no/atc` | L01XX01 | amsacrine |  |
`http://www.whocc.no/atc` | L01XX02 | asparaginase |  |
`http://www.whocc.no/atc` | L01XX03 | altretamine |  |
`http://www.whocc.no/atc` | L01XX05 | hydroxycarbamide |  |
`http://www.whocc.no/atc` | L01XX07 | lonidamine |  |
`http://www.whocc.no/atc` | L01XX08 | pentostatin |  |
`http://www.whocc.no/atc` | P01CX04 | miltefosine |  |
`http://www.whocc.no/atc` | L01XX10 | masoprocol |  |
`http://www.whocc.no/atc` | L01XX11 | estramustine |  |
`http://www.whocc.no/atc` | D10AD01 | tretinoin |  |
`http://www.whocc.no/atc` | L01XX16 | mitoguazone |  |
`http://www.whocc.no/atc` | L01CE01 | topotecan |  |
`http://www.whocc.no/atc` | L01XX18 | tiazofurine |  |
`http://www.whocc.no/atc` | L01CE02 | irinotecan |  |
`http://www.whocc.no/atc` | D11AH04 | alitretinoin |  |
`http://www.whocc.no/atc` | L01XX23 | mitotane |  |
`http://www.whocc.no/atc` | L01XX24 | pegaspargase |  |
`http://www.whocc.no/atc` | L01XF03 | bexarotene |  |
`http://www.whocc.no/atc` | L01XX27 | arsenic trioxide |  |
`http://www.whocc.no/atc` | L01XX29 | denileukin diftitox |  |
`http://www.whocc.no/atc` | L01XG01 | bortezomib |  |
`http://www.whocc.no/atc` | L01XX33 | celecoxib |  |
`http://www.whocc.no/atc` | L01XX35 | anagrelide |  |
`http://www.whocc.no/atc` | L01XX36 | oblimersen |  |
`http://www.whocc.no/atc` | L01XL01 | sitimagene ceradenovec |  |
`http://www.whocc.no/atc` | L01XH01 | vorinostat |  |
`http://www.whocc.no/atc` | L01XH02 | romidepsin |  |
`http://www.whocc.no/atc` | L01XX40 | omacetaxine mepesuccinate |  |
`http://www.whocc.no/atc` | L01XX41 | eribulin |  |
`http://www.whocc.no/atc` | L01XH03 | panobinostat |  |
`http://www.whocc.no/atc` | L01XJ01 | vismodegib |  |
`http://www.whocc.no/atc` | L01XX44 | aflibercept |  |
`http://www.whocc.no/atc` | L01XG02 | carfilzomib |  |
`http://www.whocc.no/atc` | L01XK01 | olaparib |  |
`http://www.whocc.no/atc` | L01EM01 | idelalisib |  |
`http://www.whocc.no/atc` | L01XJ02 | sonidegib |  |
`http://www.whocc.no/atc` | L01XH04 | belinostat |  |
`http://www.whocc.no/atc` | L01XG03 | ixazomib |  |
`http://www.whocc.no/atc` | L01XL02 | talimogene laherparepvec |  |
`http://www.whocc.no/atc` | L01XX52 | venetoclax |  |
`http://www.whocc.no/atc` | L01XX53 | vosaroxin |  |
`http://www.whocc.no/atc` | L01XY | Combinations of antineoplastic agents |  |
`http://www.whocc.no/atc` | G03CB02 | diethylstilbestrol |  |
`http://www.whocc.no/atc` | L02AA02 | polyestradiol phosphate |  |
`http://www.whocc.no/atc` | G03CA01 | ethinylestradiol |  |
`http://www.whocc.no/atc` | L02AA04 | fosfestrol |  |
`http://www.whocc.no/atc` | G03AC05 | megestrol |  |
`http://www.whocc.no/atc` | G03AC06 | medroxyprogesterone |  |
`http://www.whocc.no/atc` | G03DA01 | gestonorone |  |
`http://www.whocc.no/atc` | L02AE01 | buserelin |  |
`http://www.whocc.no/atc` | L02AE02 | leuprorelin |  |
`http://www.whocc.no/atc` | L02AE03 | goserelin |  |
`http://www.whocc.no/atc` | L02AE04 | triptorelin |  |
`http://www.whocc.no/atc` | L02AE05 | histrelin |  |
`http://www.whocc.no/atc` | L02BA01 | tamoxifen |  |
`http://www.whocc.no/atc` | L02BA02 | toremifene |  |
`http://www.whocc.no/atc` | L02BA03 | fulvestrant |  |
`http://www.whocc.no/atc` | L02BB01 | flutamide |  |
`http://www.whocc.no/atc` | L02BB02 | nilutamide |  |
`http://www.whocc.no/atc` | L02BB03 | bicalutamide |  |
`http://www.whocc.no/atc` | L02BB04 | enzalutamide |  |
`http://www.whocc.no/atc` | L02BG01 | aminoglutethimide |  |
`http://www.whocc.no/atc` | L02BG02 | formestane |  |
`http://www.whocc.no/atc` | L02BG03 | anastrozole |  |
`http://www.whocc.no/atc` | L02BG04 | letrozole |  |
`http://www.whocc.no/atc` | L02BG05 | vorozole |  |
`http://www.whocc.no/atc` | L02BG06 | exemestane |  |
`http://www.whocc.no/atc` | L02BX01 | abarelix |  |
`http://www.whocc.no/atc` | L02BX02 | degarelix |  |
`http://www.whocc.no/atc` | L02BX03 | abiraterone |  |
`http://www.whocc.no/atc` | L03AA02 | filgrastim |  |
`http://www.whocc.no/atc` | L03AA03 | molgramostim |  |
`http://www.whocc.no/atc` | L03AA09 | sargramostim |  |
`http://www.whocc.no/atc` | L03AA10 | lenograstim |  |
`http://www.whocc.no/atc` | L03AA12 | ancestim |  |
`http://www.whocc.no/atc` | L03AA13 | pegfilgrastim |  |
`http://www.whocc.no/atc` | L03AA14 | lipegfilgrastim |  |
`http://www.whocc.no/atc` | L03AA15 | balugrastim |  |
`http://www.whocc.no/atc` | L03AA16 | empegfilgrastim |  |
`http://www.whocc.no/atc` | L03AB01 | interferon alfa natural |  |
`http://www.whocc.no/atc` | L03AB02 | interferon beta natural |  |
`http://www.whocc.no/atc` | L03AB03 | interferon gamma |  |
`http://www.whocc.no/atc` | L03AB04 | interferon alfa-2a |  |
`http://www.whocc.no/atc` | L03AB05 | interferon alfa-2b |  |
`http://www.whocc.no/atc` | L03AB06 | interferon alfa-n1 |  |
`http://www.whocc.no/atc` | L03AB07 | interferon beta-1a |  |
`http://www.whocc.no/atc` | L03AB08 | interferon beta-1b |  |
`http://www.whocc.no/atc` | L03AB09 | interferon alfacon-1 |  |
`http://www.whocc.no/atc` | L03AB10 | peginterferon alfa-2b |  |
`http://www.whocc.no/atc` | L03AB11 | peginterferon alfa-2a |  |
`http://www.whocc.no/atc` | L03AB12 | albinterferon alfa-2b |  |
`http://www.whocc.no/atc` | L03AB13 | peginterferon beta-1a |  |
`http://www.whocc.no/atc` | L03AB14 | cepeginterferon alfa-2b |  |
`http://www.whocc.no/atc` | L03AB60 | peginterferon alfa-2b, combinations |  |
`http://www.whocc.no/atc` | L03AB61 | peginterferon alfa-2a, combinations |  |
`http://www.whocc.no/atc` | L03AC01 | aldesleukin |  |
`http://www.whocc.no/atc` | L03AC02 | oprelvekin |  |
`http://www.whocc.no/atc` | L03AX01 | lentinan |  |
`http://www.whocc.no/atc` | L03AX02 | roquinimex |  |
`http://www.whocc.no/atc` | L03AX03 | BCG vaccine |  |
`http://www.whocc.no/atc` | L03AX04 | pegademase |  |
`http://www.whocc.no/atc` | L03AX05 | pidotimod |  |
`http://www.whocc.no/atc` | L03AX07 | poly I:C |  |
`http://www.whocc.no/atc` | L03AX08 | poly ICLC |  |
`http://www.whocc.no/atc` | L03AX09 | thymopentin |  |
`http://www.whocc.no/atc` | L03AX10 | immunocyanin |  |
`http://www.whocc.no/atc` | L03AX11 | tasonermin |  |
`http://www.whocc.no/atc` | L03AX12 | melanoma vaccine |  |
`http://www.whocc.no/atc` | L03AX13 | glatiramer acetate |  |
`http://www.whocc.no/atc` | L03AX14 | histamine dihydrochloride |  |
`http://www.whocc.no/atc` | L03AX15 | mifamurtide |  |
`http://www.whocc.no/atc` | L03AX16 | plerixafor |  |
`http://www.whocc.no/atc` | L03AX17 | sipuleucel-T |  |
`http://www.whocc.no/atc` | L03AX18 | cridanimod |  |
`http://www.whocc.no/atc` | L03AX19 | dasiprotimut-T |  |
`http://www.whocc.no/atc` | L04AG01 | muromonab-CD3 |  |
`http://www.whocc.no/atc` | L04AA03 | antilymphocyte immunoglobulin (horse) |  |
`http://www.whocc.no/atc` | L04AA04 | antithymocyte immunoglobulin (rabbit) |  |
`http://www.whocc.no/atc` | L04AA06 | mycophenolic acid |  |
`http://www.whocc.no/atc` | L01EG04 | sirolimus |  |
`http://www.whocc.no/atc` | L04AK01 | leflunomide |  |
`http://www.whocc.no/atc` | L04AA15 | alefacept |  |
`http://www.whocc.no/atc` | L04AA19 | gusperimus |  |
`http://www.whocc.no/atc` | L04AG02 | efalizumab |  |
`http://www.whocc.no/atc` | L04AA22 | abetimus |  |
`http://www.whocc.no/atc` | L04AG03 | natalizumab |  |
`http://www.whocc.no/atc` | L04AA24 | abatacept |  |
`http://www.whocc.no/atc` | L04AJ01 | eculizumab |  |
`http://www.whocc.no/atc` | L04AG04 | belimumab |  |
`http://www.whocc.no/atc` | L04AE01 | fingolimod |  |
`http://www.whocc.no/atc` | L04AA28 | belatacept |  |
`http://www.whocc.no/atc` | L04AF01 | tofacitinib |  |
`http://www.whocc.no/atc` | L04AK02 | teriflunomide |  |
`http://www.whocc.no/atc` | L04AA32 | apremilast |  |
`http://www.whocc.no/atc` | L04AG05 | vedolizumab |  |
`http://www.whocc.no/atc` | L04AG07 | begelomab |  |
`http://www.whocc.no/atc` | L04AG08 | ocrelizumab |  |
`http://www.whocc.no/atc` | L04AF02 | baricitinib |  |
`http://www.whocc.no/atc` | L04AB01 | etanercept |  |
`http://www.whocc.no/atc` | L04AB02 | infliximab |  |
`http://www.whocc.no/atc` | L04AB03 | afelimomab |  |
`http://www.whocc.no/atc` | L04AB04 | adalimumab |  |
`http://www.whocc.no/atc` | L04AB05 | certolizumab pegol |  |
`http://www.whocc.no/atc` | L04AB06 | golimumab |  |
`http://www.whocc.no/atc` | L04AC01 | daclizumab |  |
`http://www.whocc.no/atc` | L04AC02 | basiliximab |  |
`http://www.whocc.no/atc` | L04AC03 | anakinra |  |
`http://www.whocc.no/atc` | L04AC04 | rilonacept |  |
`http://www.whocc.no/atc` | L04AC05 | ustekinumab |  |
`http://www.whocc.no/atc` | R03DX09 | mepolizumab |  |
`http://www.whocc.no/atc` | L04AC07 | tocilizumab |  |
`http://www.whocc.no/atc` | L04AC08 | canakinumab |  |
`http://www.whocc.no/atc` | L04AC09 | briakinumab |  |
`http://www.whocc.no/atc` | L04AC10 | secukinumab |  |
`http://www.whocc.no/atc` | L04AC11 | siltuximab |  |
`http://www.whocc.no/atc` | L04AC12 | brodalumab |  |
`http://www.whocc.no/atc` | L04AC13 | ixekizumab |  |
`http://www.whocc.no/atc` | L04AC14 | sarilumab |  |
`http://www.whocc.no/atc` | L04AD01 | ciclosporin |  |
`http://www.whocc.no/atc` | D11AH01 | tacrolimus |  |
`http://www.whocc.no/atc` | L04AD03 | voclosporin |  |
`http://www.whocc.no/atc` | L04AX01 | azathioprine |  |
`http://www.whocc.no/atc` | L04AX02 | thalidomide |  |
`http://www.whocc.no/atc` | L04AX04 | lenalidomide |  |
`http://www.whocc.no/atc` | L04AX05 | pirfenidone |  |
`http://www.whocc.no/atc` | L04AX06 | pomalidomide |  |

Explanation of the columns that may appear on this page:

Level | A few code lists that FHIR defines are hierarchical - each code is assigned a level. In this scheme, some codes are under other codes, and imply that the code they are under also applies
System | The source of the definition of the code (when the value set draws in codes defined elsewhere)
Code | The code (used as the code in the resource instance)
Display | The display (used in the display element of a Coding). If there is no display, implementers should not simply display the code, but map the concept into their application
Definition | An explanation of the meaning of the concept
Comments | Additional notes about how to use the code